INFUSE Bone Graft
Medtronic, Inc. · Decision date Feb 24, 2026
What did the FDA decide?
FDA records P050053/S067 as a supplement to PMA P050053, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 24, 2026.
FDA approval order statement
Change to upgrade the EO Sterilization Chamber Control System at the contract sterilization site from the Antares Chamber Control System to the Konnexis AccuSOLO Chamber Control System
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Dental
- Decision date
- Feb 24, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P050053/S067
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- NPZ
- Decision code
- OK30
- Decision date
- Feb 24, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Bone grafting material, dental, with biologic component.
- Applicant
- Medtronic, Inc.
- Product code
- NPZ
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P050053/S067 received
Application receipt date recorded by FDA.
P050053/S067 · FDA decision
30-Day Notice
P050053/S068 · Related supplement
INFUSE Bone Graft
P050053/S069 · Related supplement
Infuse Bone Graft
P050053/S066 · Related supplement
INFUSE BONE GRAFT
Timeline entries are records held by MedtechLedger for P050053. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P050053
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
INFUSE Bone GraftP050053/S068 | Medtronic, Inc. | PMA supplement | Mar 19, 2026 | FDA |
Infuse Bone GraftP050053/S069 | Medtronic, Inc. | PMA supplement | Jul 28, 2026 | FDA |
INFUSE BONE GRAFTP050053/S066 | Medtronic, Inc. | PMA supplement | Aug 26, 2026 | FDA |
Explore the linked device profile
Other records with product code NPZ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Lynch Biologics, LLC | PMA supplement | Aug 3, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 1800 Pyramid Pl., Memphis, TN, 38132
Sources and methodology
- Original FDA record: P050053/S067
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


